Welcome Guest




Introducing PTEN (SP218)! (News)



Media Release

New test for cancer researchers targets important tumor-suppressor protein

Highly sensitive test gives researchers a more sophisticated tool to assess PTEN protein expression in cancer cells 

PLEASANTON, Ca., September 9, 2013 – As researchers push to develop more customized diagnostics and therapies for solid tumor cancers, they demand increasingly sensitive tests that offer reliable, reproducible analysis. Spring Bioscience, Inc. (Spring) today announced a new addition to its specialized portfolio of valuable antibodies for cancer research with the introduction of the Anti-PTEN (SP218) rabbit monoclonal immunohistochemistry (IHC) antibody1.

PTEN is a common protein found in most tissues of the body. The protein acts as part of a critical cell signaling pathway that tells cells to stop dividing, helping to prevent uncontrolled cell growth that can lead to the formation of tumors. Mutations in the PTEN gene, together with other factors resulting in loss of PTEN protein, are a step in the development of many human cancers, including prostate and colon cancer. PTEN mutations are also believed to be the cause of a variety of inherited predispositions to cancer.

“With SP218, we’re seeking to set a new gold standard across the industry by offering an extremely sensitive, highly specific antibody optimized for IHC testing that will allow researchers and pathologists to interpret PTEN status with utmost confidence,” says Spring General Manager Michael Rivers. “For our customers, this means we’re continuing to offer unparalleled value through superior tests that lead the market in innovation, reliability and quality.”

Spring internal comparison studies demonstrated that SP218 provides more accurate, sensitive, and specific detection compared to similar research use only (RUO) tests on the market today. 

Overview of comparison testing, showing variations in specificity and sensitivity among SP218 and competitive anti-PTEN tests on prostate and colon samples

Image 1: Overview of comparison testing, showing variations in specificity and sensitivity among SP218 and competitive anti-PTEN tests on prostate and colon samples

Samples from more than 100 cases of primary prostate and colon cancer showed 100 percent concordance for PTEN loss among Spring’s SP218 and the leading commercially-available PTEN RUO tests; however, competitor tests exhibited some undesirable non-specific staining in IHC testing, while SP218 demonstrated highly specific staining in cells with and without PTEN expression.

“SP218’s robust and consistent performance with IHC analysis is particularly important given PTEN’s potential as a companion diagnostic biomarker,” adds Rivers. “Spring Bioscience is owned by Ventana Medical Systems, Inc., a member of the Roche group, and serves as an Antibody Center of Excellence for Roche’s companion diagnostics development to advance our goal for Personalized Healthcare.”

“Several pharma partners have embraced SP218 as their go-to antibody for PTEN IHC and are including it in their clinical trials as a potential companion diagnostic,” says Doug Ward, VP and Lifecycle Leader, Ventana Companion Diagnostics. “In addition, the Ventana Translational Diagnostics CAP/CLIA Laboratory is now using SP218 as their preferred RUO test for PTEN protein expression.”

Spring is known across the research industry for its quality development practices and for delivering a consistent supply of highly-specific antibodies. SP218 meets the company’s high standards as a valuable tool for assessing PTEN loss.


[1]The Anti-PTEN (SP218) Rabbit Monoclonal Antibody for IHC on FFPE tissue is available in 0.1, 0.5, and 1.0ml concentrate configurations, as well as 7.0mL ready-to-use. Recommended staining protocols are available for manual, semi-automated and VENTANA Discovery XT platforms for decreased assay development times.

To order or request additional information on SP218, please call (800) 787-6896 or (925) 474-8440. Orders can also be submitted via e-mail at orders@springbio.com, with technical detail available throughtech@springbio.com.

Anti-PTEN (SP218) Rabbit Monoclonal Antibody is for research use only (RUO). Not for use in diagnostic procedures.

About Spring Bioscience

Spring Bioscience, Inc. (Spring) is a leading developer of rabbit monoclonal antibodies, engineered for immunohistochemistry (IHC) and other applications in tissue-based cancer research. Founded by scientists with a primary focus on IHC, Spring has developed a proprietary menu of highly-sensitive antibodies (SP clones) that yield superior specificity and consistency in research and clinical practice. Spring is committed to high-quality development standards and also offers a portfolio of advanced detection and other complementary products for reliable, reproducible assessments of protein expression. Spring Bioscience was acquired by Ventana Medical Systems, Inc., a member of the RocheGroup, in 2007. As an antibody center of excellence for Roche with strong pharmaceutical partnerships across the industry, Spring is at the frontier of antibody development for companion diagnostics, IVD and early clinical markers.

Learn more at Springbio.com.

VENTANA, the VENTANA logo, and DISCOVERY are trademarks of Roche.

PDF Downloads

Colon adenocarcinoma stained with PTEN (SP218) antibody
Colon adenocarcinoma stained with PTEN (SP218) antibody

Prostate adenocarcinoma stained with PTEN (SP218) antibody
Prostate adenocarcinoma stained with PTEN (SP218) antibody

Request High Resolution Files


Spring Bioscience, Inc. Media Relations
Jacqueline Bucher
Senior Director, Corporate Communications
Phone: 520-877-7288
e-mail: Jacquie Bucher

© 2013 Spring Bioscience, Inc.
All trademarks are the property of their respective owners. 



Spring Bioscience to Launch exclusive BRAF V600E Antibody to the Research Market (Event)

Tucson, Ariz, May 31, 2012


Ventana signs exclusive licensing agreement for the commercialization of a novel BRAF V600E mutation antibody for cancer detection

New assay will strengthen leadership in emerging area of mutation-specific antibodies to address unmet medical needs in cancer

Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, has signed an exclusive license agreement with the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and University Hospital Heidelberg, Germany to commercialize a novel immunohistochemistry (IHC) primary antibody developed by researchers Andreas von Deimling, MD, Hanswalter Zentgraf, PhD and David Capper, MD, to detect the V600E BRAF mutation protein.  This new IHC diagnostic from Ventana will add to the already robust Roche portfolio of BRAF diagnostics. 

The BRAF protein plays a role in regulating cell signaling, and it has been shown to be mutated in many human cancers. The VENTANA antibody is being developed both as an in vitro diagnostic (IVD) and for research use only (RUO).  These products are expected to be the first validated, commercially-available IHC antibodies capable of specifically detecting BRAF mutations.  Today, cancer researchers are evaluating applications of V600E mutation testing in the diagnosis, prognosis, and prediction of patient response to therapy in major cancers including colorectal, thyroid, brain, and non-Hodgkin lymphoma. 

“Ventana is collaborating with leading cancer researchers like Paul Waring, MD, PhD at the University of Melbourne to study BRAF V600E to improve the stratification of colon cancers,” says Tom Grogan, MD, Ventana Founder and SVP, Medical Affairs.  “Specifically, we are investigating the significance of BRAF V600E mutations in the prognosis and prediction of therapy response for patients with this type of cancer.”

Andreas von Deimling, MD, Director of Neuropathology at the University Heidelberg and of DKFZ`s Clinical Cooperation Unit Neuropathology, says, “We are glad to find our mutation specific antibodies in the center of interest of so many clinicians and hope that this development will assist in improving diagnosis and directing therapy for cancer patients.”

Greg Yap, Lifecycle Leader for Advanced Staining Assays at Ventana adds, “Traditional IHC is not intended to differentiate between mutant and normal protein.  Roche, Ventana, and Spring Bioscience are leading the diagnostics industry in pioneering novel, next generation antibodies that can differentiate mutant and normal protein to enable pathologists to see clinically-relevant mutations within their cellular context.  By applying advanced antibody technology on our market-leading BenchMark automated platforms worldwide, we can deliver novel cancer diagnostic tests for significant global unmet medical needs.”

Ventana subsidiary Spring Bioscience will commercialize a BRAF V600E RUO antibody to support research applications.  This product will be commercially available May 31, 2012 through Spring Bioscience (www.springbio.com) and some of its distributors.

Ventana is currently developing the V600E BRAF mutation-specific antibody for IVD use to detect V600E BRAF mutation protein on its VENTANA BenchMark series of automated instruments utilized by thousands of anatomic pathology labs worldwide. 

 “I am very pleased to announce this exclusive licensing agreement with University Hospital Heidelberg to produce what we expect to be the first validated, commercially-available IHC antibodies capable of specifically detecting BRAF mutations to help support cancer diagnosis and inform treatment decisions,” says Mara G. Aspinall, President of Ventana Medical Systems, Inc.  It is another example of our ongoing commitment to improving patients’ lives with the most advanced diagnostic solutions available globally.”

About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. (“VMSI”) (SIX: RO, ROG; OTCQX: RHHBY), a member of the
Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company’s intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of “companion diagnostics” to identify the patients most likely to respond favorably to specific therapies.
Visit www.ventana.com to learn more.

VENTANA, the VENTANA logo, and BenchMark are trademarks of Roche.

VMSI Media Relations

Jacqueline Bucher
Senior Director, Corporate Communications
Phone: 520-877-7288
e-mail: jacquie.bucher@ventana.roche.com

About Deutsches Krebsforschungszentrum, DKFZ:
The German Cancer Research Center (DKFZ) with its more than 2,500 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg where promising approaches from cancer research are translated into the clinic. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. The center is a member of the Helmholtz Association of National Research Centers. Ninety percent of its funding comes from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

About Heidelberg University Hospital:
Heidelberg University Hospital and the Medical Faculty of Heidelberg University
Patient Care, Research and Teaching of International Standard
Heidelberg University Hospital is among the largest and most renowned medical centers in Germany. The Medical Faculty of Heidelberg University ranges among the internationally relevant biomedical research institutes in Europe. The common goal is to develop new therapies and to apply them rapidly for the benefit of the patient. The Hospital and the Faculty have approximately 11,000 employees  and  are active in training and qualification. In more than 50 departments, clinics and special departments with about 2,000 hospital beds, approximately 600,000 patients receive inpatient and outpatient treatment each year. There are currently about 3,600 aspiring doctors studying medicine in Heidelberg; the Heidelberg Curriculum Medicinale (HeiCuMed) is at the top of medical teaching and training in Germany.


Roche acquires Mariposa Bioscience, Inc. to enhance its R&D capabilities for rabbit monoclonal antibodies (Event)

On Friday, August 20th 2010, Roche completed the acquisition of Mariposa Bioscience, Inc., (Mariposa), a Burlingame, California-based privately held company. This acquisition will enhance Roche Tissue Diagnostics’ antibody development capabilities which are a foundational component of today’s clinical assays and tomorrow’s companion diagnostics. 
Mariposa was founded in 2006 with a small team of antibody and molecular scientists who developed and established proprietary technology to clone monoclonal antibodies directly from peripheral blood B cells of non-rodent species without the need for a hybridoma fusion partner (see explanation below). Rabbit monoclonal antibodies are considered more sensitive in clinical applications than antibodies derived from other species, and Mariposa’s technology develops rabbit monoclonal antibodies more quickly than other companies in the industry. As a result, providing researchers, pathologists and their patients with high specificity, quality results that lead to accurate diagnosis. 
Hany Massarany, Head of Roche Tissue Diagnostics said, “We are excited about the addition of Mariposa’s world-class researchers, scientists and technology. Mariposa brings a wealth of expertise that will translate into products which provide both our research and diagnostic customers with strategic and effective antibody biomarkers for assessing protein expression in tissue. With Spring, they will further complement our antibody portfolio with advanced detection and ancillary products that are valuable in field of immunohistochemistry and most importantly with companion diagnostics.” 
Mariposa has been collaborating with Spring Bioscience, a wholly-owned subsidiary of Roche Tissue Diagnostics/Ventana, for the past three years. During this period, the two companies have worked together to validate the technology, and develop a series of rabbit monoclonal antibodies. Many of these antibodies have been launched as new in vitro diagnostic products at Roche Tissue Diagnostics. 
Dr. Robert Pytela, Co-Founder and CEO of Mariposa said, “Mariposa has had a successful collaboration with Spring over the last three years. Roche is the ideal company to build upon our technology to deliver innovative in vitro diagnostics (IVD) products. Therefore, Mariposa and its shareholders are very pleased to have found a strong partner.” 
Mariposa’s employees will move to Spring’s facilities located in Pleasanton, California. “We share Ventana’s commitment to innovate cancer diagnostics for patients battling cancer, and are excited to become part of the Roche group,” stated Dr. Jas Villanueva, Co-Founder and COO of Mariposa.

For further information please see: 
            - Mariposa: http://mariposabio.com
            - Spring: http://www.springbio.com
            - Roche Tissue Diagnostics: http://www.ventana.com


Novel Rabbit Monoclonal Antibodies Technology Established at Spring! (Event)

As of April 2010 Spring Bioscience Corporation successfully developed a novel and robust process for making rabbit monoclonal antibodies.
Spring Bioscience has long recognized the benefits of rabbit monoclonal antibodies for their specificity and high affinity which makes them ideally suited to deliver optimal results in immunohistochemistry as well as other immunoassay. Through partnership with collaborators, Spring pioneered a series of rabbit monoclonal antibodies in the immunohistochemistry market. Spring’s SP clones have proven themselves time and time again as gold standards in the immunohistochemistry markers and this breakthrough will serve to further this leadership position. 
After nearly a year of internal R&D, our scientists have generated an advanced rabbit monoclonal technology that will allow us to accelerate our delivery of a broader menu of these best-in-class antibodies to the market.